Skip to main content

The role of mesenchymal stromal cells in immune modulation of COVID-19: focus on cytokine storm


The outbreak of coronavirus disease 2019 (COVID-19) pandemic is quickly spreading all over the world. This virus, which is called SARS-CoV-2, has infected tens of thousands of people. Based on symptoms, the pathogenesis of acute respiratory illness is responsible for highly homogenous coronaviruses as well as other pathogens. Evidence suggests that high inflammation rates, oxidation, and overwhelming immune response probably contribute to pathology of COVID-19. COVID-19 causes cytokine storm, which subsequently leads to acute respiratory distress syndrome (ARDS), often ending up in the death of patients. Mesenchymal stem cells (MSCs) are multipotential stem cells that are recognized via self-renewal capacity, generation of clonal populations, and multilineage differentiation. MSCs are present in nearly all tissues of the body, playing an essential role in repair and generation of tissues. Furthermore, MSCs have broad immunoregulatory properties through the interaction of immune cells in both innate and adaptive immune systems, leading to immunosuppression of many effector activities. MSCs can reduce the cytokine storm produced by coronavirus infection. In a number of studies, the administration of these cells has been beneficial for COVID-19 patients. Also, MSCs may be able to improve pulmonary fibrosis and lung function. In this review, we will review the newest research findings regarding MSC-based immunomodulation in patients with COVID-19.


The city of Wuhan was the origin of coronavirus disease (COVID-19), a severe acute respiratory syndrome with SARS-CoV-2 as its causative agent. Presently, COVID-19 infection has spread to all continents of the world [1]. Due to unknown reasons, COVID-19 infection has been widely distributed in various geographical regions with high population densities [2]. Moreover, the profile of symptoms and severity of COVID-19 infection show extensive variation in different parts of the world [3]. Worldwide assessments suggest that only 3.4% of those infected with SARS-CoV-2 have perished as a result of COVID-19, which also shows high difference in various parts of the world [4].

Constant fever, non-productive cough, dyspnea, myalgia, fatigue, normal or reduced WBC counts, hyperferritinemia, and radiographic evidence of pneumonia are among the clinical signs of patients with COVID-19, which are similar to the symptoms of infection by other members of this family, namely SARS-CoV and the Middle East respiratory syndrome-related coronavirus (MERS-CoV) [5,6,7]. The mortality rate of the new coronavirus, known as SARS-CoV-2, is high because of insufficient knowledge about the pathogenesis of COVID-19, and no specific treatment has been recognized for it [8]. On the other hand, the response to COVID-19 infection can be overwhelmed in many patients. When SARS-CoV-2 enters into the lungs, it unleashes an immune response, attracting immune cells to the region attacked by the virus and resulting in localized inflammation [9]. In some cases, excessive or unchecked levels of cytokines are released that can be fatal due to an overreaction of the immune system, which is referred to as a cytokine storm [10]. The cytokine storm can trigger organ injury and cause edema, gas exchange dysfunction, acute respiratory distress syndrome (ARDS), acute cardiac injury, and secondary infection, which can be potentially fatal [11].

Consequently, the inhibition of cytokine storm is a main factor in the treatment of patients who are infected with SARS-CoV-2. Currently, available therapies for COVID-19 include non-specific antiviral drugs, antibiotics used for the treatment of secondary bacterial infections, sepsis, and reduction of inflammation [12]. A large number of anti-inflammatory medications have been developed, including NSAIDs, glucocorticoids, chloroquine/hydroxychloroquine, antagonists of inflammatory cytokines (such as IL-6R monoclonal antibodies, TNF inhibitors, IL-1 antagonists), and Janus kinase JAK inhibitors [13, 14]. However, in severe cases of ARDS, it is a difficult task to treat the cytokine storm induced by the virus. The findings suggest that stem cell-based therapy is applicable to treat infected patients.

Mesenchymal stromal cells and their features

Mesenchymal stromal cells (MSCs) are the cells with the unique ability to exert suppressive and regulatory effects on the immune system [15]. MSCs have been the focus of research because evidence has indicated that MSCs are able to migrate to and return from damaged tissues, exercise potent anti-inflammatory and immune regulatory activities, support the regeneration and repair of tissues, resist against apoptosis, inhibit tissue fibrosis, and decrease tissue injury [16]. MScs are able to migrate to site of lesion and differentiate into tissue-specific active cells such as lung, smooth muscle, and nerve cells [17]. Following intravenous or intra-arterial infusion of MSCs, these cells are primarily trapped in capillary beds of the liver and lungs [18]. MSC homing processes are not fully realized but are known to involve a variety of molecules such as chemokine receptors, including CCR2, CCR4, CCR7, CCR10, CXCR5, CXCR6, and CXCR4, adhesion proteins, and matrix metalloproteinase (MMPs), namely molecules also implicated in the well-known process of leukocyte extravasation [19, 20]. Hypoxia and inflammation are frequent indications of an injured tissue capable of affecting paracrine features of MSCs, which are mainly mediated via VEGF, FGF2, IGF-1, and HGF [21].

When MSCs are trapped in the lungs, a wide range of soluble mediators are secreted by them, including antimicrobial peptides, anti-inflammatory cytokines, extracellular vesicles, and angiogenic growth factors [22]. The release pattern of anti-inflammatory mediators is unique to the inflammatory lung environment, which is adjusted by differential damage and pathogen-associated molecular receptors that are expressed on MSCs [23], namely TLRs (toll-like receptors). As for COVID-19, TLRs are stimulated by viral unmethylated CpF-DNA (TLR9) as well as viral RNA (TLR3), leading to sequential cellular signaling pathways and the activation of MSCs [24].

On the other hand, inflammation leads to nuclear factor-kappa B (NF-κB) and c-Jun NH2-terminal kinase (JNK) signaling, which is also controlled through the factors secreted by MSCs. In addition, lung damage improves during the response of MSCs to oxidative stress, cytoprotection, and phosphoinositide 3-kinase/protein kinase B (P13K / Akt) signaling pathway [25]. Administration of BM-MSCs alleviated lung injury in a preclinical study via potentiating the PI3K/Akt signaling pathway [26, 27].

For example, the release of IL-1ra through MSCs inhibits IL-α/β activity via generating TSG-6, which is followed by the downregulation of NF-κB signaling and reduced production of inflammatory cytokines. Secretion of prostaglandin E2 (PGE2) is another efficient way to decrease inflammation by MSCs, which is a function of IL-10 production as a strong anti-inflammatory cytokine. Khakoo et al. showed that MSCs prevent PKB signaling of target cells via a contact-dependent way [28].

MSCs encounter a complex setting specified by various chemical and physical stimuli while moving toward an injured tissue and the microenvironment impacts MSCs’ behavior [29]. MSCs are able to release many types of cytokines through paracrine release or direct interaction with immune cells, which leads to immunomodulation [30]. These cells have the capacity to interact with immune cells in innate and adaptive immune systems [31]. Besides, MSC-mediated immunosuppression depends on the combined reaction of chemokines, inflammatory cytokines, and effector factors, as along with the microenvironment and the rate of inflammatory stimulus [32]. Owing to their powerful immunomodulatory ability, MSCs might have beneficial effects for preventing or attenuating the cytokine storm of SARS-CoV-2 infection [33, 34]. This paper tries to explain the significant role of MSCs in secreting important factors for immune regulation in COVID-19.

The SARS-CoV-2 infection and cytokine storm

ARDS caused by cytokine storm is the main mortality factor in COVID-19 [35]. The lethally uncontrolled systemic inflammatory response is stimulated by the secretion of a large number of pro-inflammatory cytokines such as interleukin (IL)-1β, IL-2, IL-6, IL-7, IL-12, IL-18, IL-33, interferon (IFN)-α, IFN-γ, tumor necrosis factor-α (TNFα), granulocyte colony-stimulating factor (GSCF), interferon-γ inducible protein 10 (IP10), monocyte chemoattractant protein 1 (MCP1), macrophage inflammatory protein 1-α (MIP1A), and transforming growth factor-beta (TGF-β) such as chemokines by immune effector cells within coronavirus infection (Fig. 1) [36,37,38].

Fig. 1

Immunomodulation effect of mesenchymal stem cells on cytokines storm led by COVID-19. When SARS-CoV-2 enters the lungs, it attracts immune cells to infection areas and localizes inflammation. The lethal unchecked systemic inflammatory response is caused by the secretion of large levels of pro-inflammatory cytokines such as interleukin, interferons, chemokines, and other factors by immune effector cells in this infection. After MSC therapy, these cells reach the lung tissue and secrete factors that can modulate the immune system; they also can prevent ROS and even fibrosis of the lung tissue. Abbreviation: ARDS: acute respiratory distress syndrome, COVID-19: coronavirus disease 2019, CCL: chemokine (C-C motif) ligand, CXCL: chemokine (C-X-C motif) ligand, C3: Complement component 3, CRP: C-reactive protein, DC reg: regulatory dendritic cells, GSCF: granulocyte colony-stimulating factor, HO-1: Heme oxygenase-1, HLA-G5: human leukocyte antigen-G, IL: interleukin, IFN: interferon, IP10: IFN-γ-Inducible Protein 10, IL-1RA: interleukin-1 receptor antagonist, LIF: leukemia inhibitory factor, IDO: Indoleamine 2,3-dioxygenase, MSCs: mesenchymal stem cells, MIP1A: Macrophage Inflammatory Protein 1 Alpha, MCP1: monocyte chemoattractant protein 1, NKCs: natural killer cells, NO: nitric oxide, PERIF: peripheral, PGE2: Prostaglandin E2, ROS: reactive oxygen species, SARS-CoV: severe acute respiratory-associated coronavirus, SOD-3: superoxide dismutase, TSG-6: TNFα-stimulated gene-6, TGF-β: transforming growth factor, Treg: regulatory T

Huang et al. reported the level of inflammatory factors among patients with COVID-19. They measured cytokines of patients with COVID-19 and indicated increasing levels of IL-1B, IL-1RA, IL-7, IL-8, IL-9, IL-10, fibroblast growth factor (FGF), granulocyte-macrophage colony-stimulating factor (GM-CSF), IFN-γ, G-CSF, IP10, MCP1, MIP1A, PDGF, TNFα, and vascular endothelial growth factor (VEGF) in their specimens, among which TNFα levels were higher in patients with severe disease. Remarkably, no significant difference was observed in serum IL-6 levels between ICU and non-ICU admitted patients [8]. Nevertheless, in a retrospective, multicenter cohort study, the same research group reported a significant elevation of IL-6 levels in patients not surviving COVID-19 as compared with survivors [39]. Several other reports have also confirmed increasing IL-6 levels among critically ill COVID-19 patients [24, 40]. Moreover, the result of another study demonstrated that a majority of severe COVID-19 patients in ICU had persistently elevated levels of ESR and CRP, as well as high levels of IL-6, TNFα, IL-1β, IL-8, and IL2R, and experienced ARDS, hypercoagulation, and disseminated intravascular coagulation (DIC) [13].

The cytokine storm was followed by ARDS and multiple organ failure, which causes death in severe cases of COVID-19. For example, the findings of Huang et al. showed that out of 41 infected patients who were admitted in the early stages, 6 patients died as a result of ARDS [8]. Like common acute viral infections, both humoral and cellular immunity are activated in COVID-19. Therefore, inhibition of cytokine storm may be the key to the treatment of COVID-19 patients.

Immunomodulatory effects of MSCs

MSCs show remarkable immunomodulatory capacity and are implicated in both innate and adaptive immune systems. Former investigations on immune regulation of MSCs have concentrated on interactions of MSCs and B lymphocytes, natural killer (NK) cells, and dendritic cells (DC) [41]. Lately, the application of MSCs in repairing damaged tissue and adjustment of inflammatory reactions have become noticed considering macrophage and T lymphocyte regulation (Fig. 1) [16]. Interaction mechanisms have been shown to be dependent upon cell-cell contact along with the release of soluble immune factors to induce MSC-regulated immunosuppression [42]. The cells that express immunosuppressive ligands like programmed death-ligand 1 (PD-L1) and Fas ligand (Fas-L) on their surface bind receptors present on the surface of immune cells, which leads to loss of function in immune cells [43, 44].

Several studies have revealed that the anti-inflammatory effect of MSCs can alleviate virus-induced lung injury and mortality in mice [45, 46]. Research has indicated that MSCs are able to significantly reduce acute lung injury by H9N2 and H5N1 viruses in mice by decreasing levels of pro-inflammatory cytokines and chemokines as well as diminishing the recruitment of inflammatory cells into the lungs [47, 48]. Applying MSCs to interfere in endotoxin (LPS)-induced acute lung injury of mice proved that MSCs can remarkably lead to reduction of inflammatory cell infiltration in lung tissue, alleviate inflammation, and improve the lung tissue from endotoxin-induced damage [49, 50].

Intravenous infusion of MSCs normally results in their accumulation within lungs, whereby they secrete many paracrine factors [51]. Evidence suggests that MSCs bind activated immune cells, which could keep them in close proximity and hence potentiate immunosuppressive effects [52]. Moreover, MSCs can also prevent the function of immune cells via releasing cytokines such as TGF-β, HGF, and prostaglandin E2 (PGE2), as along with other anti-inflammatory factors [53]. For example, MSCs secrete TGF-β and other factors promoting the induction of regulatory T lymphocytes (Tregs) and M2 macrophages, transmitting the immunosuppressive effects to other cells in order to activate various immunosuppressive mechanisms [54]. MSCs express TNFα-stimulated gene/protein 6 (TSG-6) that mediates the regulation of immune inflammation (Fig. 1) [55]. TSG-6 is another key factor with a crucial role in tissue repair activity of human MSCs that has been proven in mouse models of myocardial infarction, peritonitis, and acute corneal and lung injury [23, 56]. TSG-6 antagonizes the binding of CXCL8 to heparin via interaction with the GAG-binding site of CXCL8, which inhibits CXCL8-mediated chemotaxis of neutrophils. Furthermore, TSG-6 can prevent the extravasation of leukocytes (especially neutrophils and macrophages) at the inflammation site [57].

In COVID-19 cases, MSCs are able to increase the lymphocyte count and regulatory DCs to raise their antiviral characteristic which results in the decreased level of C-reactive protein and pro-inflammatory cytokines (IL-6, TNFα, IL-8, and so on) that are the main markers of inflammation and ROS to diminish the inflammation and oxidative stress [58]. On the other hand, MSCs can increase the level of IL-10 as an anti-inflammatory protein activating regulatory cells such as Tregs (Fig. 1) [59]. Therefore, MSCs play a central role in immune homeostasis by interacting with cytokines, chemokines, and cell surface molecules. Put together, all these immunomodulatory features contribute to the extensive potential of MSCs in clinical therapies.

MSC-based therapy in COVID-19 patients

The capacity of MSCs in multilineage differentiation and immunomodulation signifies that these somatic progenitor cells are extremely versatile in many therapeutic applications [60]. In fact, as of April 2016, more than 500 MSC-related clinical trials have been recorded on the NIH Clinical Trial Database ( [61].

The safety and efficacy of transplanted MSCs for the alleviation of inflammatory lung diseases appears to be demonstrated in experimental models [62]. MSCs have been extensively used in cell-based therapies from basic research to clinical trials [63,64,65]. Inflammation has been recognized to affect several morbid processes in the pulmonary system, which include obstructive diseases such as chronic obstructive pulmonary diseases (COPD) and asthma, along with restrictive diseases such as idiopathic pulmonary fibrosis (IPF) and (ARDS). The acute and chronic lung injury observed in these diseases always involves abnormal immune activity and fibrosis either as a cause or a consequence [66, 67]. Similar to most cell therapies, MSC therapy could be useful in lung disease because it has been demonstrated that many intravenously delivered MSCs (80–90%) will rapidly reach the lungs when delivered through intravenous injection [68]. Following systemic administration, a majority of MSCs lodge in the pulmonary vascular bed through unknown interactions with the capillary endothelial cells. Tracking studies using labeled MSCs demonstrate that most MSCs are cleared within 24–48 h although there can be longer persistence of them in injured or inflamed lungs [69]. Several phase I/II clinical trials have been done to determine the safety of MSC infusions in patients afflicted with ARDS. In China, Zheng et al. observed no serious adverse events associated with MSC administration in 12 patients with ARDS [70]. Besides, Wilson et al. showed that a single intravenous MSC infusion up to 106 cells/kg was well tolerated in nine patients with moderate to severe ARDS [71]. Matthay and colleagues reported a prospective, double-blind, randomized clinical trial evaluating the effect of a single systemic dose of allogeneic bone marrow-derived MSCs (107 cells/kg) in comparison with placebo (2:1 ratio). This research demonstrated that no hemodynamic or respiratory abnormal events associated with MSC infusion were seen over a follow-up period of 60 days and that the 28-day death rate was higher in the MSC group relative to the placebo, which was not remarkably different between the groups [72]. Furthermore, the novel avian-origin influenza A (H7N9) virus with single-stranded RNA segments and COVID-19 has comparable complications (e.g., ARDS and lung failure), as well as corresponding multi-organ dysfunction together with inflammatory lung lesions and structural damage [73, 74]. Thus, advances in finding a therapeutic approach for H7N9 infection in human beings would be essential for treating COVID-19, especially severe ARDS-induced pneumonia that has presently provoked panic in every corner of the world [8, 75, 76]. Wilson et al. [71] have recently found that the administration of allogeneic MSCs for nine patients with ARDS did not lead to any particular adverse events such as cardiac arrhythmia, hypoxemia, and ventricular tachycardia. MSCs taken from menstrual blood have recently become attractive because of easy access, high rate of proliferation, and a non-invasive procedure lacking ethical issues [77,78,79]. Chen et al. argue that MSCs are capable of reducing inflammatory effects and avoiding cytokine storm. MSCs are an encouraging tool for treatment of acute pneumonia for prospective clinical application [14]. A recent study in China revealed that administration of intravenous injection of MSCs significantly improved the inflammation situation in severe COVID-19 patients. Ultimately, the patients with severe COVID-19 pneumonia survived the worst condition and entered recovery. Also, they said that the level of TNFα was significantly decreased, while IL-10 increased in MSC treatment group [80].

It should be mentioned that just a few cell therapy studies for ARDS and sepsis have reached their primary goals in randomized investigations [81, 82]. Scientists approve that targeted clinical research is essential whilst the first reports of MSC use for COVID-19 over the early phase of COVID-19 breakout in China have presented valuable clues that the therapeutic measures could be rather safe and efficient [83,84,85]. Few conclusions can be derived from these early studies because of the low number of subjects (typically ≤ 10) and the absence of adequate control groups [58, 80, 86]. Proper design of clinical trials and the observation of quality factors such as the documentation of patients, inclusion/exclusion criteria, classification of treatment approaches, primary and secondary statistics, timing and dosing of treatments, and comedication are immediately needed [85, 87]. While preliminary results may appear to be promising, the previous failures of innovative clinical research with MSCs as well as the low number of registered MSC products should be kept in mind [88,89,90,91,92]. Several problems have been identified in this respect, including failed upscaling of the product to large-scale supply and the absence of translation to efficient clinical application (e.g., cell expansion from the starting material, cell viability problems after thawing, and suboptimal delivery route) [82, 93,94,95,96], which could account for the failure of different studies [88, 89]. A key issue for sustainable marketing would be the technological adequacy of the products and manufacturers in case some of the advanced phase II/III clinical studies show solid evidence supporting the approval of product in future (as discussed below) [90, 91]. The unprecedented dynamics of COVID-19 pandemic as well as the high number of deaths all over the world indicate that large-scale manufacturing and comprehensive logistic capacity are required to supply enough doses of high-quality cellular products in a reproducible and chronological manner [97]. SARS-CoV-2 enters into cells through the recognition of cellular transmembrane protease serine 2 (TMPRSS2) and angiotensin I converting enzyme 2 receptor (ACE2). ACE2 receptors have been detected in the heart (endothelium of coronary arteries, myocytes, fibroblasts, epicardial adipocytes), blood vessels (vascular endothelial and smooth cells), gut (intestinal epithelial cells), lung (tracheal and bronchial epithelial cells, type 2 pneumocytes, macrophages), kidney (luminal surface of tubular epithelial cells), brain, and testis [98]. In the human lung, the wide surface area of alveolar epithelial cells could account for the vulnerability of this organ to negative sequelae of COVID-19 infiltration. A main point is that ACE2 receptors are largely expressed in type II pneumocytes, i.e., small cylinder-shaped cells representing 5% of all pneumocytes [99] that are responsible for the generation of alveolar surfactant while acting as “stem” cells and progenitors of type I pneumocytes (95% of pneumocytes) performing gas exchanges in lungs [100,101,102].

SARS-Cov and SARS-CoV2 bind ACE2 receptors, leading to membrane fusion and virus penetration into the cell, thereby causing the downregulation of these receptors [98, 103]. In other words, the virus seems to enter into the cell together with the membrane receptor, which is subsequently removed from the external surface of the membrane.

The ACE2 gene lies on X chromosome and it has been shown that potential functional variants of ACE2 gene alter its transcriptional activity. Nevertheless, the pattern of population distribution influencing differential susceptibility to SARS-CoV-2 and the genetic origin of differential ACE2 expression and its functional implications among different populations are barely known [104]. Hypertension and diabetes mellitus (DM) are the most frequent comorbid conditions in COVID-19 and both are modulated by ACE2. Loss of ACE2 disturbs the balance of renin-angiotensin system, impairing vascular function and exacerbating cardiovascular complications of diabetes [105]. It appears that higher severity of COVID-19 among those suffering from high blood pressure and DM could be driven at least partially by pathological deviations from the ACE2 pathway. Accordingly, ACE2 appears to be crucial in the outcome of COVID-19as well as the role it plays in susceptibility [106].

A major function of ACE2 has also been proven in inflammatory processes [107]. Genetic deficiency of ACE2 leads to upregulated expression of cytokines, inducing vascular inflammation in ApoE knockout mouse models [108]. In a recent research, ACE2 expression was related with several immune signatures such as markers of T cells, B cells, and NK cells, as well as interferon response in various human tissues [109]. These results suggest that ACE2 not only acts as a receptor of SARS-CoV-2 but takes part in mediation of post-infection downstream processes, including inflammatory responses. Furthermore, the gene expression profile of MSCs shows that ACE2 and TMPRSS2 are not expressed in these cells, so MSCs are not infected by a coronavirus. RNA-seq survey to identify 12,500 transplanted MSC during follow-up revealed that the cells had not been differentiated and remained ACE2 negative. ACE2 expression is observed in other tissues like the heart, liver, kidney, and digestive organs [80].

Such an expression pattern explains the reason why infected ICU patients are afflicted not only with ARDS but also other complications of multiple organ dysfunction syndromes [110]. The mechanisms that account for the improvement observed following MSC infusion in COVID-19 patients seem to be indicative of the strong anti-inflammatory activity of these cells [80]. Two recent studies from China on COVID-19 patients reveal a marked reversal of symptoms even in severe and critical conditions [58, 80]. Consequently, their clinical researches recognize a new remedial strategy and the presence of natural mechanisms capable of defeating acute inflammatory pneumonia. One study was a case report of a critically ill COVID-19 patient on a ventilator with progressive disease despite undergoing intensive therapy with markers showing liver injury. The patient was treated using allogeneic human umbilical cord MSC (hUC-MSC) and three intravenous infusions of 5 × 107 hUC-MSC 3 days later. Within 4 days of the first cell infusion, the patient was detached from the ventilator and was able to walk. All the parameters under study such as circulating T lymphocytes returned to normal. Low levels of lymphocytes could be due to their sequestration within the inflamed lungs and tissues. No noticeable side effects were observed [58].

The second study [80] by Leng et al. demonstrated that intravenous MSC infusion prevents the immune system from overactivation and repairs the lung microenvironment affected by SARS-CoV-2 infection even in older patients. Intravenous infusion of MSCs normally results in the accumulation of these cells in the lungs and release of several paracrine factors [111]. MSC infusion is useful especially in older people infected with SARS-CoV-2 because this group is more susceptible to pneumonia from SARS-CoV-2, resulting in severe respiratory distress and mortality because of immunosenescence [112,113,114]. It is proved that the intravenous infusion of MSCs is a safe and efficient orientation for treating patients infected by COVID-19 pneumonia, including older people with severe pneumonia [115].

Nowadays, several clinical trials using stem cell therapy to treat the coronavirus have been recorded from China, Iran, USA, Columbia, France, Denmark, Jordan, and Saudi Arabia, which are listed at,, and summarized in Table 1.

Table 1 Overview of planned or ongoing studies of cell therapy for the treatment of COVID-19

Concussion and future perspective

Given the prevalence of COVID-19 and its complications such as cytokine storm, which is followed by ARDS and death of patients, finding a way to treat and improve the patients is of high importance [116]. As mentioned in this paper, there is no specific therapy for this virus and supportive therapies as well as non-specific antiviral drugs are mainly used for this purpose. Today, cell therapy is a modern method for treating a variety of diseases and several studies have been conducted in recent months to treat the SARS-CoV-2 virus using stem cells, suggesting the application of MSCs or immune cells such as NK cells [33, 117, 118]. According to research on MSC-based therapy, the safety and immunomodulatory role of MSCS in ARDS have been approved [82]. MSCs can secrete factors that improve the lung microenvironment, inhibit immune system overactivation, promote tissue repair, rejuvenate alveolar epithelial cells, inhibit pulmonary counteracting fibrosis, or improve function in damaged lung tissue because of SARS-CoV-2 infection [119, 120].

Many issues related to the application of MSCs, including the ideal dose and optimum timing of MSC delivery, should be further explored. In several animal models of human diseases, the use of secretory exosomes from MSCs has been claimed to mimic the beneficial effects of MSCs in antiviral therapy for influenza virus, reducing virus replication in lungs and virus-induced release of pro-inflammatory cytokines [121, 122]. Experimental studies and ongoing randomized trials will play an essential role in the clarification of the therapeutic potential of MSCs, which further our understanding of how MSCs interact with lung tissue infected by SARS-CoV-2.

Availability of data and materials

Not applicable.


  1. 1.

    Rothan HA, Byrareddy SNJJ. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak; 2020. p. 102433.

    Google Scholar 

  2. 2.

    Sajadi MM, Habibzadeh P, Vintzileos A, Shokouhi S, Miralles-Wilhelm F, Amoroso AJAS. Temperature and latitude analysis to predict potential spread and seasonality for COVID-19; 2020.

    Google Scholar 

  3. 3.

    Park M, Cook AR, Lim JT, Sun Y, Dickens BL. A Systematic Review of COVID-19 Epidemiology Based on Current Evidence. J Clin Med. 2020;9(4):967.

  4. 4.

    Debnath M, Banerjee M, Berk MJTFJ. Genetic gateways to COVID-19 infection: implications for risk, severity, and outcomes; 2020.

    Google Scholar 

  5. 5.

    Zu ZY, Jiang MD, Xu PP, Chen W, Ni QQ, Lu GM, et al. Coronavirus disease 2019 (COVID-19): a perspective from China; 2020. p. 200490.

    Google Scholar 

  6. 6.

    Wacharapluesadee S, Duengkae P, Rodpan A, Kaewpom T, Maneeorn P, Kanchanasaka B, et al. Diversity of coronavirus in bats from Eastern Thailand. 2015;12(1):57.

  7. 7.

    Prompetchara E, Ketloy C, Palaga TJAPJAI. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. 2020;38(1):1–9.

  8. 8.

    Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England). 2020;395(10223):497–506.

    CAS  Article  Google Scholar 

  9. 9.

    Astuti I, Ysrafil. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response. Diabetes Metab Syndr. 2020;14(4):407–12. Epub 2020 Apr 18. PMID: 32335367; PMCID: PMC7165108.

  10. 10.

    Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJJTL. COVID-19: consider cytokine storm syndromes and immunosuppression. 2020;395(10229):1033–4.

  11. 11.

    Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). 2020.

    Google Scholar 

  12. 12.

    NITULEScU GM, PAUNEScU H, MOScHOS SA, Petrakis D, Nitulescu G, Ion GND, et al. Comprehensive analysis of drugs to treat SARS-CoV-2 infection: mechanistic insights into current COVID-19 therapies. 2020.

    Google Scholar 

  13. 13.

    Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. Clin Immunol. 2020;214:108393.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  14. 14.

    Chen C, Zhang XR, Ju ZY, He WF. Advances in the research of cytokine storm mechanism induced by Corona Virus Disease 2019 and the corresponding immunotherapies. Zhonghua Shao Shang Za Zhi. 2020;36(0):E005.

    Google Scholar 

  15. 15.

    Ai J, Ketabchi N, Verdi J, Gheibi N, Khadem Haghighian H, Kavianpour M. Mesenchymal stromal cells induce inhibitory effects on hepatocellular carcinoma through various signaling pathways. Cancer Cell Int. 2019;19(1):329.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  16. 16.

    Li H, Shen S, Fu H, Wang Z, Li X, Sui X, et al. Immunomodulatory functions of mesenchymal stem cells in tissue engineering. Stem Cells Int. 2019;2019:9671206.

    PubMed  PubMed Central  Google Scholar 

  17. 17.

    Han Y, Li X, Zhang Y, Han Y, Chang F, Ding J. Mesenchymal stem cells for regenerative medicine. Cells. 2019;8(8):886.

    CAS  PubMed Central  Article  Google Scholar 

  18. 18.

    Leibacher J, Henschler R. Biodistribution, migration and homing of systemically applied mesenchymal stem/stromal cells. Stem Cell Res Ther. 2016;7(1):7.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  19. 19.

    Ullah M, Liu DD, Thakor AS. Mesenchymal stromal cell homing: mechanisms and strategies for improvement. iScience. 2019;15:421–38.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  20. 20.

    Ghaffari-Nazari HJJSCRM. The known molecules involved in MSC homing and migration. 2018;3:1–4.

  21. 21.

    Ejtehadifar M, Shamsasenjan K, Movassaghpour A, Akbarzadehlaleh P, Dehdilani N, Abbasi P, et al. The effect of hypoxia on mesenchymal stem cell biology. Adv Pharm Bull. 2015;5(2):141–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  22. 22.

    Walter J, Ware LB, Matthay MAJTLRM. Mesenchymal stem cells: mechanisms of potential therapeutic benefit in ARDS and sepsis. 2014;2(12):1016–26.

  23. 23.

    Prockop DJ, Oh JYJM. Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Mol Ther. 2012;20(1):14–20.

    CAS  PubMed  Article  Google Scholar 

  24. 24.

    Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020;55(5):105954.

  25. 25.

    Ai J, Ketabchi N, Verdi J, Gheibi N, Haghighian HK, Kavianpour MJCCI. Mesenchymal stromal cells induce inhibitory effects on hepatocellular carcinoma through various signaling pathways. 2019;19(1):1–13.

  26. 26.

    Yan X-I, Fu C-J, Chen L, Qin J-H, Zeng Q, Yuan H-F, et al. Mesenchymal stem cells from primary breast cancer tissue promote cancer proliferation and enhance mammosphere formation partially via EGF/EGFR/Akt pathway. Breast Cancer Res Treat. 2012;132(1):153–64.

    CAS  PubMed  Article  Google Scholar 

  27. 27.

    Arslan F, Lai RC, Smeets MB, Akeroyd L, Choo A, Aguor EN, et al. Mesenchymal stem cell-derived exosomes increase ATP levels, decrease oxidative stress and activate PI3K/Akt pathway to enhance myocardial viability and prevent adverse remodeling after myocardial ischemia/reperfusion injury. 2013;10(3):301–12.

  28. 28.

    Khakoo AY, Pati S, Anderson SA, Reid W, Elshal MF, Rovira II, et al. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J Exp Med. 2006;203(5):1235–47.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  29. 29.

    Sohni A, Verfaillie CMJS. Mesenchymal stem cells migration homing and tracking, vol. 2013; 2013.

    Google Scholar 

  30. 30.

    Follin B, Juhl M, Cohen S, Pedersen AE, Kastrup J, Ekblond AJTEPBR. Increased paracrine immunomodulatory potential of mesenchymal stromal cells in three-dimensional culture. 2016;22(4):322–9.

  31. 31.

    Najar M, Raicevic G, Fayyad-Kazan H, Bron D, Toungouz M, Lagneaux LJC. Mesenchymal stromal cells and immunomodulation: a gathering of regulatory immune cells. 2016;18(2):160–71.

  32. 32.

    Chiossone L, Conte R, Spaggiari GM, Serra M, Romei C, Bellora F, et al. Mesenchymal stromal cells induce peculiar alternatively activated macrophages capable of dampening both innate and adaptive immune responses. 2016;34(7):1909–21.

  33. 33.

    Jeyaraman M, Somasundaram R, Anudeep TC, Ajay SS, Vinodh KV, Jain R, et al. Mesenchymal stem cells (mscs) as a novel therapeutic option for nCOVID-19—a review. 2020;9(2):20–35.

  34. 34.

    Khoury M, Cuenca J, Cruz FF, Figueroa FE, Rocco PR, Weiss DJJERJ. Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19; 2020.

    Google Scholar 

  35. 35.

    Wu C, Chen X, Cai Y, Zhou X, Xu S, Huang H, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. 2020.

    Google Scholar 

  36. 36.

    Metcalfe SM. Mesenchymal stem cells and management of COVID-19 pneumonia. Med Drug Discovery. 2020;5:100019.

    Article  Google Scholar 

  37. 37.

    Liu B, Li M, Zhou Z, Guan X, Xiang Y. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? J Autoimmun. 2020:102452.

  38. 38.

    Conti P, Ronconi G, Caraffa A, Gallenga CE, Ross R, Frydas I, Kritas SK. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020;34(2):1.

  39. 39.

    Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. 2020.

    Google Scholar 

  40. 40.

    Alzghari SK, Acuna VS. Supportive treatment with Tocilizumab for COVID-19: a systematic review. J Clin Virol. 2020:104380.

  41. 41.

    Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood. 2007;110(10):3499–506.

    CAS  PubMed  Article  Google Scholar 

  42. 42.

    Kean TJ, Lin P, Caplan AI, Dennis JEJS. MSCs: delivery routes and engraftment, cell-targeting strategies, and immune modulation, vol. 2013; 2013.

    Google Scholar 

  43. 43.

    Ostrand-Rosenberg S, Horn LA, Haile ST. The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity. J Immunol. 2014;193(8):3835–41.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  44. 44.

    Strasser A, Jost PJ, Nagata S. The many roles of FAS receptor signaling in the immune system. Immunity. 2009;30(2):180–92.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  45. 45.

    Khatri M, Richardson LA, Meulia T. Mesenchymal stem cell-derived extracellular vesicles attenuate influenza virus-induced acute lung injury in a pig model. Stem Cell Res Ther. 2018;9(1):1–13.

    Article  CAS  Google Scholar 

  46. 46.

    Waszak P, Alphonse R, Vadivel A, Ionescu L, Eaton F, Thébaud B. Preconditioning enhances the paracrine effect of mesenchymal stem cells in preventing oxygen-induced neonatal lung injury in rats. Stem Cells Dev. 2012;21(15):2789–97.

    CAS  PubMed  Article  Google Scholar 

  47. 47.

    Li Y, Xu J, Shi W, Chen C, Shao Y, Zhu L, et al. Mesenchymal stromal cell treatment prevents H9N2 avian influenza virus-induced acute lung injury in mice. Stem Cell Res Ther. 2016;7(1):159.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  48. 48.

    Chan MCW, Kuok DIT, Leung CYH, Hui KPY, Valkenburg SA, Lau EHY, et al. Human mesenchymal stromal cells reduce influenza a H5N1-associated acute lung injury in vitro and in vivo. Proc Natl Acad Sci U S A. 2016;113(13):3621–6.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  49. 49.

    Curley GF, Jerkic M, Dixon S, Hogan G, Masterson C, O’Toole D, et al. Cryopreserved, xeno-free human umbilical cord mesenchymal stromal cells reduce lung injury severity and bacterial burden in rodent Escherichia coli–induced acute respiratory distress syndrome. Crit Care Med. 2017;45(2):e202–e12.

    PubMed  Article  Google Scholar 

  50. 50.

    Lee JW, Fang X, Krasnodembskaya A, Howard JP, Matthay MA. Concise review: mesenchymal stem cells for acute lung injury: role of paracrine soluble factors. Stem Cells. 2011;29(6):913–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  51. 51.

    Wysoczynki M, Khan A, Bolli R. New paradigms in cell therapy: repeated dosing, intravenous delivery, immunomodulatory actions, and new cell types. Circ Res. 2018;123(2):138–58.

    CAS  PubMed Central  Article  Google Scholar 

  52. 52.

    Quaedackers ME, Baan CC, Weimar W, Hoogduijn MJ. Cell contact interaction between adipose-derived stromal cells and Allo-activated T lymphocytes. Eur J Immunol. 2009;39(12):3436–46.

    CAS  PubMed  Article  Google Scholar 

  53. 53.

    Van Den Akker F, Deddens J, Doevendans P, Sluijter J. Cardiac stem cell therapy to modulate inflammation upon myocardial infarction. Biochim Biophys Acta (BBA) General Subjects. 2013;1830(2):2449–58.

    Article  CAS  Google Scholar 

  54. 54.

    Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood J Am Soc Hematol. 2002;99(10):3838–43.

    Google Scholar 

  55. 55.

    Choi H, Lee RH, Bazhanov N, Oh JY, Prockop DJ. Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-κB signaling in resident macrophages. Blood J Am Soc Hematol. 2011;118(2):330–8.

    CAS  Google Scholar 

  56. 56.

    Oh JY, Roddy GW, Choi H, Lee RH, Ylöstalo JH, Rosa RH, et al. Anti-inflammatory protein TSG-6 reduces inflammatory damage to the cornea following chemical and mechanical injury. Proc Natl Acad Sci. 2010;107(39):16875–80.

    CAS  PubMed  Article  Google Scholar 

  57. 57.

    Dyer DP, Thomson JM, Hermant A, Jowitt TA, Handel TM, Proudfoot AE, et al. TSG-6 inhibits neutrophil migration via direct interaction with the chemokine CXCL8. J Immunol. 2014;192(5):2177–85.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  58. 58.

    Liang B, Chen J, Li T, Wu H, Yang W, Li Y, et al. Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells. ChinaXiv. 2020;2:v1.

    Google Scholar 

  59. 59.

    Lim J-Y, Im K-I, Lee E-S, Kim N, Nam Y-S, Jeon Y-W, et al. Enhanced immunoregulation of mesenchymal stem cells by IL-10-producing type 1 regulatory T cells in collagen-induced arthritis. Sci Rep. 2016;6:26851.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  60. 60.

    Griffin MD, Elliman SJ, Cahill E, English K, Ceredig R, Ritter T. Concise review: adult mesenchymal stromal cell therapy for inflammatory diseases: how well are we joining the dots? Stem Cells. 2013;31(10):2033–41.

    CAS  PubMed  Article  Google Scholar 

  61. 61.

    Wang L-T, Ting C-H, Yen M-L, Liu K-J, Sytwu H-K, Wu KK, et al. Human mesenchymal stem cells (MSCs) for treatment towards immune- and inflammation-mediated diseases: review of current clinical trials. J Biomed Sci. 2016;23(1):76.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  62. 62.

    Harrell CR, Sadikot R, Pascual J, Fellabaum C, Jankovic MG, Jovicic NA-O, et al. Mesenchymal stem cell-based therapy of inflammatory lung diseases: current understanding and future perspectives. (1687-966X (Print)).

  63. 63.

    Connick P, Kolappan M Fau - Crawley C, Crawley C Fau - Webber DJ, Webber Dj Fau - Patani R, Patani R Fau - Michell AW, Michell Aw Fau - Du M-Q, et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. (1474–4465 (Electronic)).

  64. 64.

    Wilson JG, Liu KD, Zhuo H, Caballero L, McMillan M, Fang X, et al. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. (2213–2619 (Electronic)).

  65. 65.

    Saleh M, Taher M, Sohrabpour AA, Vaezi AA, Nasiri Toosi M, Kavianpour M, et al. Perspective of placenta derived mesenchymal stem cells in acute liver failure. Cell Biosci. 2020;10:1–11.

    Article  Google Scholar 

  66. 66.

    Inamdar AC, Inamdar AA. Mesenchymal stem cell therapy in lung disorders: pathogenesis of lung diseases and mechanism of action of mesenchymal stem cell. Exp Lung Res. 2013;39(8):315–27.

    CAS  PubMed  Article  Google Scholar 

  67. 67.

    Walter J, Ware LB, Matthay MA. Mesenchymal stem cells: mechanisms of potential therapeutic benefit in ARDS and sepsis. (2213–2619 (Electronic)).

  68. 68.

    Anjos-Afonso F, Siapati EK, Bonnet D. In vivo contribution of murine mesenchymal stem cells into multiple cell-types under minimal damage conditions. J Cell Sci. 2004;117(23):5655–64.

    CAS  PubMed  Article  Google Scholar 

  69. 69.

    Armitage J, Tan DB, Troedson R, Young P, Lam K-V, Shaw K, et al. Mesenchymal stromal cell infusion modulates systemic immunological responses in stable COPD patients: a phase I pilot study. Eur Respir J. 2018;51(3):1702369.

    PubMed  Article  CAS  Google Scholar 

  70. 70.

    Zheng G, Huang L, Tong H, Shu Q, Hu Y, Ge M, et al. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study. Respir Res. 2014;15(1):39.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  71. 71.

    Wilson JG, Liu KD, Zhuo H, Caballero L, McMillan M, Fang X, et al. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med. 2015;3(1):24–32.

    PubMed  Article  Google Scholar 

  72. 72.

    Matthay MA, Calfee CS, Zhuo H, Thompson BT, Wilson JG, Levitt JE, et al. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. Lancet Respir Med. 2019;7(2):154–62.

    PubMed  Article  Google Scholar 

  73. 73.

    Vlachakis D, Karozou A, Kossida SJIr, treatment. 3D molecular modelling study of the H7N9 RNA-dependent RNA polymerase as an emerging pharmacological target. 2013;2013.

  74. 74.

    Imai M, Watanabe T, Kiso M, Nakajima N, Yamayoshi S, Iwatsuki-Horimoto K, et al. A highly pathogenic avian H7N9 influenza virus isolated from a human is lethal in some ferrets infected via respiratory droplets. 2017;22(5):615–26. e8.

  75. 75.

    Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–2.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  76. 76.

    Gao C, Wang Y, Gu X, Shen X, Zhou D, Zhou S, et al. Community-acquired pneumonia-China N. association between cardiac injury and mortality in hospitalized patients infected with Avian Influenza A (H7N9) virus. 2020;48(4):451–8.

  77. 77.

    Khoury M, Alcayaga-Miranda F, Illanes SE, Figueroa FE. The promising potential of menstrual stem cells for antenatal diagnosis and cell therapy. Front Immunol. 2014;5:205.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  78. 78.

    Chen L, Qu J, Cheng T, Chen X, Xiang C. Menstrual blood-derived stem cells: toward therapeutic mechanisms, novel strategies, and future perspectives in the treatment of diseases. Stem Cell Res Ther. 2019;10(1):406.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  79. 79.

    Chen L, Qu J, Xiang C. The multi-functional roles of menstrual blood-derived stem cells in regenerative medicine. Stem Cell Res Ther. 2019;10(1):1–10.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  80. 80.

    Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, et al. Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis. 2020;11(2):216–28.

    PubMed  PubMed Central  Article  Google Scholar 

  81. 81.

    Wang T, Chen R, Liu C, Liang W, Guan W, Tang R, et al. Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19. Lancet Haematol. 2020;7(5):e362–e3.

    PubMed  PubMed Central  Article  Google Scholar 

  82. 82.

    Cruz FF, Rocco PRM. Cell therapy for acute respiratory distress syndrome patients: the START study. J Thorac Dis. 2019;11(Suppl 9):S1329.

    PubMed  PubMed Central  Article  Google Scholar 

  83. 83.

    Khoury M, Rocco PRM, Phinney DG, Krampera M, Martin I, Viswanathan S, Nolta JA, LeBlanc K, Galipeau J, Weiss DJ. Cell-Based Therapies for COVID-19: Proper Clinical Investigations are Essential. Cytotherapy. 2020. Epub ahead of print. PMCID: PMC7163352.

  84. 84.

    Khoury M, Cuenca J, Cruz FF, Figueroa FE, Rocco PRM, Weiss DJ. Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19. Eur Respir J. 2020;55(6):2000858. PMID: 32265310; PMCID: PMC7144273.

  85. 85.

    London AJ, Kimmelman J. Against pandemic research exceptionalism. Science. 2020;368(6490):476–7.

    CAS  PubMed  Article  Google Scholar 

  86. 86.

    Ji F, Li L, Li Z, Jin Y, Liu W. Mesenchymal stem cells as a potential treatment for critically ill patients with coronavirus disease 2019. Stem Cells Transl Med. 2020.

  87. 87.

    Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006;3(9):e343.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  88. 88.

    Galipeau J, Sensébé L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 2018;22(6):824–33.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  89. 89.

    Weiss DJ, English K, Krasnodembskaya A, Isaza-Correa JM, Hawthorne IJ, Mahon BP. The necrobiology of mesenchymal stromal cells affects therapeutic efficacy. Front Immunol. 2019;10:1228.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  90. 90.

    Abou-El-Enein M, Bauer G, Reinke P. The business case for cell and gene therapies. Nat Biotechnol. 2014;32(12):1192–3.

    CAS  PubMed  Article  Google Scholar 

  91. 91.

    Abou-El-Enein M, Elsanhoury A, Reinke P. Overcoming challenges facing advanced therapies in the EU market. Cell Stem Cell. 2016;19(3):293–7.

    CAS  PubMed  Article  Google Scholar 

  92. 92.

    Sheridan C. First off-the-shelf mesenchymal stem cell therapy nears European approval. Nature Biotechnology. 2018;36(3):212–4.

  93. 93.

    Moll G, Ankrum JA, Kamhieh-Milz J, Bieback K, Ringdén O, Volk H-D, et al. Intravascular mesenchymal stromal/stem cell therapy product diversification: time for new clinical guidelines. Trends Mol Med. 2019;25(2):149–63.

    PubMed  Article  Google Scholar 

  94. 94.

    Moll G, Alm JJ, Davies LC, von Bahr L, Heldring N, Stenbeck-Funke L, et al. Do cryopreserved mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties? Stem Cells. 2014;32(9):2430–42.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  95. 95.

    Moll G, Geißler S, Catar R, Ignatowicz L, Hoogduijn MJ, Strunk D, Bieback K, Ringdén O. Cryopreserved or Fresh Mesenchymal Stromal Cells: Only a Matter of Taste or Key to Unleash the Full Clinical Potential of MSC Therapy? Adv Exp Med Biol. 2016;951:77–98. PMID: 27837556.

  96. 96.

    Giri J, Galipeau J. Mesenchymal stromal cell therapeutic potency is dependent upon viability, route of delivery, and immune match. Blood Adv. 2020;4(9):1987–97.

    PubMed  PubMed Central  Article  Google Scholar 

  97. 97.

    Moll G, Drzeniek N, Kamhieh-Milz J, Geissler S, Volk H-D, Reinke P. MSC therapies for COVID-19: importance of patient coagulopathy, thromboprophylaxis, cell product quality and mode of delivery for treatment safety and efficacy. Front Immunol. 2020;11:1091.

    PubMed  PubMed Central  Article  Google Scholar 

  98. 98.

    Verdecchia P, Cavallini C, Spanevello A, Angeli FJEJIM. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection; 2020.

    Google Scholar 

  99. 99.

    Hamming I, Timens W, Bulthuis M, Lely A. Navis Gv, van Goor HJTJoPAJotPSoGB, et al. tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. 2004;203(2):631–7.

  100. 100.

    Barkauskas CE, Cronce MJ, Rackley CR, Bowie EJ, Keene DR, Stripp BR, et al. Type 2 alveolar cells are stem cells in adult lung. 2013;123(7):3025–36.

  101. 101.

    Rajaei S, Dabbagh A. The immunologic basis of COVID-19: a clinical approach. 2020. 2020;5(1):6 %J Journal of Cellular & Molecular Anesthesia.

  102. 102.

    Qi J, Zhou Y, Hua J, Zhang L, Bian J, Liu B, et al. The scRNA-seq expression profiling of the receptor ACE2 and the cellular protease TMPRSS2 reveals human organs susceptible to COVID-19 infection. bioRxiv. 2020; 2020.04.16.045690.

  103. 103.

    Zhang H, Penninger JM, Li Y, Zhong N, Slutsky ASJI. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. 2020;46(4):586–90.

  104. 104.

    Lu N, Yang Y, Wang Y, Liu Y, Fu G, Chen D, et al. ACE2 gene polymorphism and essential hypertension: an updated meta-analysis involving 11,051 subjects. 2012;39(6):6581–9.

  105. 105.

    Patel VB, Bodiga S, Basu R, Das SK, Wang W, Wang Z, et al. Loss of angiotensin-converting enzyme-2 exacerbates diabetic cardiovascular complications and leads to systolic and vascular dysfunction: a critical role of the angiotensin II/AT1 receptor axis. 2012;110(10):1322–35.

  106. 106.

    Devaux CA, Rolain J-M, Raoult DJJoM, Immunology, Infection. ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome. 2020.

  107. 107.

    Reddy Gaddam R, Chambers S, Bhatia MJI, Targets A-D. ACE and ACE2 in inflammation: a tale of two enzymes. 2014;13(4):224–34.

  108. 108.

    Thomas MC, Pickering RJ, Tsorotes D, Koitka A, Sheehy K, Bernardi S, et al. Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse. 2010;107(7):888–97.

  109. 109.

    Li M-Y, Li L, Zhang Y, Wang X-SJI. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. 2020;9:1–7.

  110. 110.

    Geng Y-J, Wei Z-Y, Qian H-Y, Huang J, Lodato R, Castriotta RJ. Pathophysiological characteristics and therapeutic approaches for pulmonary injury and cardiovascular complications of coronavirus disease 2019. Cardiovasc Pathol. 2020:107228.

  111. 111.

    Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL, et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell. 2009;5(1):54–63.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  112. 112.

    Shetty AK, Upadhya R, Madhu LN, Kodali M. Novel insights on systemic and brain aging, stroke, amyotrophic lateral sclerosis, and Alzheimer’s disease. Aging Dis. 2019;10(2):470.

    PubMed  PubMed Central  Article  Google Scholar 

  113. 113.

    Shetty AK, Kodali M, Upadhya R, Madhu LN. Emerging anti-aging strategies-scientific basis and efficacy. Aging Dis. 2018;9(6):1165.

    PubMed  PubMed Central  Article  Google Scholar 

  114. 114.

    Thomas R, Wang W, Su D-M. Contributions of age-related thymic involution to Immunosenescence and Inflammaging. Immun Ageing. 2020;17(1):1–17.

    Article  CAS  Google Scholar 

  115. 115.

    Shetty AK. Mesenchymal stem cell infusion shows promise for combating coronavirus (COVID-19)-induced pneumonia. Aging Dis. 2020;11(2):462.

    PubMed  PubMed Central  Article  Google Scholar 

  116. 116.

    Yi Y, Lagniton PNP, Ye S, Li E, Xu R-H. COVID-19: what has been learned and to be learned about the novel coronavirus disease. Int J Biol Sci. 2020;16(10):1753–66.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  117. 117.

    Monteil V, Kwon H, Prado P, Hagelkrüys A, Wimmer RA, Stahl M, et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. 2020.

    Google Scholar 

  118. 118.

    Ji H, Yan Y, Ding B, Guo W, Brunswick M, Niethammer A, et al. Novel decoy cellular vaccine strategy utilizing transgenic antigen-expressing cells as immune presenter and adjuvant in vaccine prototype against SARS-CoV-2 virus, vol. 100026; 2020.

    Google Scholar 

  119. 119.

    Foronjy RF, Majka SM. The potential for resident lung mesenchymal stem cells to promote functional tissue regeneration: understanding microenvironmental cues. Cells. 2012;1(4):874.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  120. 120.

    Golchin A, Seyedjafari E, Ardeshirylajimi A. Mesenchymal stem cell therapy for COVID-19: present or future. Stem Cell Rev Rep. 2020:1–7.

  121. 121.

    Khatri M, Richardson LA, Meulia T. Mesenchymal stem cell-derived extracellular vesicles attenuate influenza virus-induced acute lung injury in a pig model. Stem Cell Res Ther. 2018;9(1):17.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  122. 122.

    Bruno S, Deregibus MC, Camussi G. The secretome of mesenchymal stromal cells: role of extracellular vesicles in immunomodulation. Immunol Lett. 2015;168(2):154–8.

    CAS  PubMed  Article  Google Scholar 

Download references


Not applicable.


This work was supported by the Tehran University of Medical Sciences.

Author information




MK, JV, and MS contributed to the concept of the review. MK, JV, and MS were responsible for the reference selection and writing of the manuscript. MK and MS contributed to the critical review of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Mahshid Saleh.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kavianpour, M., Saleh, M. & Verdi, J. The role of mesenchymal stromal cells in immune modulation of COVID-19: focus on cytokine storm. Stem Cell Res Ther 11, 404 (2020).

Download citation


  • Mesenchymal stromal cells
  • COVID-19
  • Immune regulatory
  • Cytokine storm